Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sherene Loi

Showing results (161-170 of 325) with videos related to

Pageof 33
Sort By:
Journal of the National Cancer Institute|May 11, 2023
Tucatinib promotes immune activation and synergizes with programmed cell death-1 and programmed cell death-ligand 1 inhibition in HER2-positive breast cancerRan Li, Sneha Sant, Emmaline Brown, et al.
Cancer Research|January 17, 2020
Activation of Canonical BMP4-SMAD7 Signaling Suppresses Breast Cancer MetastasisBedrich L Eckhardt, Yuan Cao, Andrew D Redfern, et al.
JAMA Oncology|June 15, 2018
Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical TrialRyan L Powles, David Redmond, Christos Sotiriou, et al.
JAMA Oncology|June 15, 2018
Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical TrialStephen J Luen, Rebecca Asher, Chee Khoon Lee, et al.
JAMA Oncology|July 17, 2015
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO TrialRoberto Salgado, Carsten Denkert, Christine Campbell, et al.
Genome Biology|October 2, 2014
Deciphering clonality in aneuploid breast tumors using SNP array and sequencing dataIngrid M Lönnstedt, Franco Caramia, Jason Li, et al.
Plos Medicine|October 1, 2020
Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort studyAndjelija Zivanovic Bujak, Chen-Fang Weng, Maria João Silva, et al.
Drug Safety|August 8, 2023
Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary PanelJoanne Wing Yan Chiu, Soo Chin Lee, James Chung-Man Ho, et al.
Nature Communications|November 29, 2024
Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trialMattia Rediti, David Venet, Andrea Joaquin Garcia, et al.
Breast Cancer Research : BCR|July 15, 2022
Correction to: Clinical implications of prospective genomic profiling of metastatic breast cancer patientsCourtney T van Geelen, Peter Savas, Zhi Ling Teo, et al.
Pageof 33

Showing results (161-170 of 325) with videos related to

Sort By:
Pageof 33
Journal of the National Cancer Institute|May 11, 2023
Tucatinib promotes immune activation and synergizes with programmed cell death-1 and programmed cell death-ligand 1 inhibition in HER2-positive breast cancerRan Li, Sneha Sant, Emmaline Brown, et al.
Cancer Research|January 17, 2020
Activation of Canonical BMP4-SMAD7 Signaling Suppresses Breast Cancer MetastasisBedrich L Eckhardt, Yuan Cao, Andrew D Redfern, et al.
JAMA Oncology|June 15, 2018
Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical TrialRyan L Powles, David Redmond, Christos Sotiriou, et al.
JAMA Oncology|June 15, 2018
Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical TrialStephen J Luen, Rebecca Asher, Chee Khoon Lee, et al.
JAMA Oncology|July 17, 2015
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO TrialRoberto Salgado, Carsten Denkert, Christine Campbell, et al.
Genome Biology|October 2, 2014
Deciphering clonality in aneuploid breast tumors using SNP array and sequencing dataIngrid M Lönnstedt, Franco Caramia, Jason Li, et al.
Plos Medicine|October 1, 2020
Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort studyAndjelija Zivanovic Bujak, Chen-Fang Weng, Maria João Silva, et al.
Drug Safety|August 8, 2023
Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary PanelJoanne Wing Yan Chiu, Soo Chin Lee, James Chung-Man Ho, et al.
Nature Communications|November 29, 2024
Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trialMattia Rediti, David Venet, Andrea Joaquin Garcia, et al.
Breast Cancer Research : BCR|July 15, 2022
Correction to: Clinical implications of prospective genomic profiling of metastatic breast cancer patientsCourtney T van Geelen, Peter Savas, Zhi Ling Teo, et al.
Pageof 33